Suzano Reports a Strong Second Quarter Performance With Record Cash Generation
28.7.2022 00:30:00 EEST | Business Wire | Press release
Suzano , one of the world’s largest integrated pulp and paper producers, announces its second quarter results for 2022.
- Adjusted EBITDA of R$6.3 billion, up 6% on 2Q21 (R$5.9 billion)
- Operating cash generation of R$5.1 billion, up 2% on 2Q21 (R$4.9 billion)
- Net revenue of R$11.5 billion, up 17% on 2Q21 (R$9.8 billion)
-
Substantial sales volume increase:
- 5% increase in pulp sales volumes to 2.66 million tons (2Q21: 2.54 million tons)
- 10% increase paper sales volumes to 324,000 tons (2Q21: 296,000 tons)
- Net debt to EBITDA leverage ratio of 2.3x (1Q22: 2.4x)
- Increased 2022 CAPEX guidance of R$16.1 billion from previously announced R$13.6 billion
Strong second quarter performance across these financial verticals was driven by both higher sales prices, given more favourable market conditions for pulp and paper markets; and higher sales volumes, given fewer scheduled maintenance shutdowns. Cost management discipline also improved adjusted EBITDA and cash generation.
“These excellent second quarter results are not only testament to higher pulp prices and positive market demand, but as well as the continued efforts of our various teams to ensure Suzano boosts operational efficiency. With this firm financial and operational footing, Suzano is intent on expanding our capacity to create, and share, value with our stakeholders,” said Walter Schalka, CEO of Suzano.
The Cerrado Project, a new pulp plant which is being built in Mato Grosso do Sul state, is progressing precisely as scheduled, closing the second quarter of 2022 with a physical progress "inside-the-fence" of 21%. This one plant alone will create up to 10,000 direct jobs during construction and 3,000 new employment opportunities once operational.
The second quarter also saw the acquisition of land properties, the launch of Suzano Ventures, and new plans to build a consumer goods plant in Espírito Santo. Additionally, in recent months Suzano has announced a higher dividend payment in 2022 and a share buyback program, with a new buyback program announced today.
On a social front, Suzano intends to double the number of beneficiaries attended by its social programs to 50,000 people in 2022. Meanwhile, on an environmental front, the numerous projects under development include one of the largest landscape restoration programs in Brazil, covering 35,000 hectares of areas under restoration, and the goal of connecting 500,000 hectares of forest fragments by 2030.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005783/en/
Contact information
Hawthorn Advisors
Jamie Plotnek
suzano@hawthornadvisors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 15:00:00 EET | Press release
Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap widens, confidence erodes and competitive advantage is lost. Orchestrated Planning removes decision latency by harmonizing data, people, processes and agentic capabilities to help organizations mo
Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 15:00:00 EET | Press release
Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expansion plans, strategic drivers, and regulatory challenges.1 CSC’s report Navigating U.S. Market Entry: Insights, Risks, and Opportunities for Global Businesses details the results. The research highlights strong forward momentum toward U.S. expansion. In addition to the 45% planning to establish an entity within the next 12 months, a further 27% s
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 14:30:00 EET | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The recently completed Phase 1 clinical trial, conducted in the European Union, was designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496—the first-ever GPX4 (selective glutathione peroxidase 4) modulator to be studied in human trials, and the first specifically targeting cellular rejuvenation, an area of great interest to the scientific community as a new therapeutic pathway. The study met its primary endpoint, with RLS-1496 also demonstrating early signs of efficacy. Preliminary Trial Results RLS-1496 was well-tolerated,
GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 14:30:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by the expanding use of highly effective antitumor therapies - including chemotherapy, radiotherapy and targeted therapies - many of which are associated with cardiovascular toxicities. Global studiesi show that heart-related complications are now the second leading cause of death in cancer survivors, after the cancer itself, accounting for
Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 14:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom